OFFICAL PROJECT SITE
Novel Target for Treatment of Chronic Inflammatory Diseases — Notid
Lipum attracts interest from life science leaders
Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn [...]
Lipum and Abzena sign integrated CMC agreement
Press release march 19 2019 Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel [...]
Umeåföretag tar nästa steg mot ett nytt läkemedel
Pressrelease 3 juni, 2019 Ladda ned pressrelase: Investerare satsar 25 MSEK på nytt läkemedel (pdf) » Umeåföretaget Lipum utvecklar ett biologiskt läkemedel för behandling av kroniska inflammationer. Tidigare pre-kliniska studier har visat mycket goda resultat och potential att ge en bättre behandling av till exempel ledgångsreumatism. ”Konkurrensen i branschen är [...]
Lipum to NASDAQ
On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for EIC pilot- funded companies with the opportunity to pitch their business to top European investors and connect with Nasdaq representatives [...]
New share issue round about to close on Sunday 17 February
Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. The capital will finance the preclinical work and the development of a production method up to the start of toxicology studies next year. See the full [...]
Lipum on the list of Swedish startups who receive millions from the EU
"Sweden is number eight on the list of European countries that receive the most money" says Johan Lindberg at Vinnova, who helps Swedish companies to apply for EU grants. So far, Sweden has received SEK 10 billion through the EU Innovation Fund Horizon 2020, of which 25 million was allocated [...]
Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741
Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases
Project budget:
3.2 M€
Funding from the EU:
2.2 M€
Start:
2018-11-01
End:
2020-07-31